Company Filing History:
Years Active: 2024
Title: Nike Beaubier: Innovator in Cancer Research Technology
Introduction
Nike Beaubier is a prominent inventor based in Chicago, IL (US), known for his significant contributions to cancer research and treatment technologies. With a focus on data-driven methodologies, he has developed innovative systems that aim to enhance the understanding and treatment of cancer.
Latest Patents
Nike Beaubier holds a patent for a groundbreaking invention titled "Data based cancer research and treatment systems and methods." This patent outlines a method and system that involves storing a set of user application programs, each requiring an application-specific subset of data to perform application processes. The system generates a respective genomic variant characterization for each of a plurality of patients with cancerous cells undergoing treatment. The method includes obtaining clinical records data, generating genomic sequencing data for the patient's cancerous and normal cells, and shaping the genomic sequencing data to create structured data. This structured data is stored in a database, facilitating the selection and storage of application-specific data for interfacing with user application programs.
Career Highlights
Nike Beaubier is currently employed at Tempus AI, Inc., where he continues to push the boundaries of cancer research through innovative technology. His work is instrumental in developing systems that integrate clinical data with genomic information, ultimately aiming to improve patient outcomes in cancer treatment.
Collaborations
Nike collaborates with talented individuals in his field, including Christopher Shane Colley and Isaiah Simpson. These partnerships enhance the research and development efforts at Tempus AI, Inc., fostering an environment of innovation and discovery.
Conclusion
Nike Beaubier's contributions to cancer research through his patented technologies exemplify the impact of innovation in the medical field. His work not only advances scientific understanding but also holds the potential to transform patient care in oncology.